Our group is dedicated to unraveling the mechanisms underlying T cell dysfunction in human cancer. At the heart of our pursuit lies the development and validation of advanced genetically-directed CAR T cells as targeted immunotherapy. Our keen focus extends to the realm of epigenetic programming of immune cells and elucidating the signaling and molecular requirements essential for the generation of effective memory and effector T cell responses. Our groundbreaking research hopes to revolutionize the fight against cancer and pave the way for novel therapeutic approaches.